LabCorp bids for test company
at Investor's Business Daily - Thu Sep 25, 5:53PM CDT
Medical-testing giant Laboratory Corp. of America (LH) agreed to buy cholesterol-test startup LipoScience (LPDX) for $85.3 mil in cash, driving the latter's shares up sharply. LipoScience makes a lipid profile test using nuclear magnetic resonance...
EQUITY ALERT: Rosen Law Firm Announces Investigation of LipoScience, Inc. Concerning its Proposed Sale to LabCorp - LPDX
Business Wire - Thu Sep 25, 5:02PM CDT
The Rosen Law Firm, P.A. announces that it is investigating the Board of Directors of LipoScience, Inc. (NASDAQ:LPDX) for possible breaches of fiduciary duty and other violations of law by failing to adequately shop LipoScience to maximize shareholder value before agreeing to be acquired by Laboratory Corporation of America Holdings (NYSE: LH).
Law Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of LipoScience, Inc. Stockholders
Business Wire - Thu Sep 25, 4:58PM CDT
Kirby McInerney LLP is investigating potential claims against LipoScience, Inc. ("LipoScience" or the "Company"
LIPOSCIENCE, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
Business Wire - Thu Sep 25, 12:55PM CDT
Rigrodsky & Long, P.A.:
Acquisition Announcement Spurs LipoScience Surge
at The Street - Thu Sep 25, 11:44AM CDT
LipoScience Inc (NASDAQ:LPDX), Magnum Hunter Resources Corp (NYSE:MHR) and Corinthian Colleges Inc (NASDAQ:COCO) are today's top-gaining billionaire stock picks midday. On the losing end are NII H...
SHAREHOLDER ALERT: Pomerantz LLP Investigates Claims That the Merger May Not Be in the Best Interest of Investors of LipoScience, Inc. - LPDX
PR Newswire - Thu Sep 25, 11:05AM CDT
Pomerantz LLP is investigating claims on behalf of investors of LipoScience, Inc. ("LipoScience" or the "Company"
LabCorp Acquiring Cholesterol Tester LipoScience
at Investor's Business Daily - Thu Sep 25, 10:49AM CDT
Medical-testing giant Laboratory Corp. of America (LH) agreed to buy startup LipoScience (LPDX) for $85.3 million in cash Thursday, sending the latter's shares up more than 62% in the stock market today. LipoScience makes a lipid profile test using...
LIPOSCIENCE SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Sale to Laboratory Corporation of America
Business Wire - Thu Sep 25, 10:36AM CDT
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of LipoScience, Inc. ("LipoScience"
Why LipoScience (LPDX) Stock Is Jumping Today
at The Street - Thu Sep 25, 9:21AM CDT
LipoScience (LPDX) is gaining Thursday after LabCorp (LH) announced it will acquire the specialized cardiovascular diagnostic laboratory test provider.
LIPO SCIENCE SHAREHOLDER ALERT: Proposed Sale of LipoScience, Inc. under Investigation by Johnson & Weaver, LLP in Connection with the Proposed Sale of the Company to Laboratory Corporation of America Holdings
Business Wire - Thu Sep 25, 7:33AM CDT
Shareholder rights law firm Johnson & Weaver, LLP has launched an investigation into whether the board members of LipoScience, Inc. (Nasdaq: LPDX) breached their fiduciary duties in connection with the proposed sale of the Company to Laboratory Corporation of America Holdings (LabCorp).
LabCorp Announces Agreement to Acquire LipoScience
Business Wire - Thu Sep 25, 6:00AM CDT
--NMR LipoProfile test expands LabCorp's offering of personalized diagnostic tests
Silver Spring Networks Starts The Week Strong
at The Street - Mon Sep 08, 12:30PM CDT
Silver Spring Networks Inc (NYSE:SSNI), Essent Group Ltd (NYSE:ESNT) and LipoScience Inc (NASDAQ:LPDX) are today's top-gaining billionaire stock picks midday. Having a tough start to the week are ...
LipoScience Announces 2014 Second Quarter Financial Results
GlobeNewswire - Tue Aug 12, 4:41PM CDT
Achieves Second Quarter Revenue Guidance
LipoScience to Release Second Quarter 2014 Financial Results
GlobeNewswire - Mon Aug 04, 3:15PM CDT
LipoScience, Inc. (Nasdaq:LPDX) today announced that it will release its second quarter 2014 financial results after the market close on Tuesday, August 12, 2014. An investor conference call will follow on the same day at 4:30 P.M. ET.
Study Published in Atherosclerosis Provides First Large-Scale, Real-World Evidence of Link Between Low LDL Particle Levels and Reduced Risk of Cardiovascular Disease
PR Newswire - Tue Jun 24, 7:00AM CDT
LipoScience, Inc. (NASDAQ: LPDX), today announced the publication of the first large-scale real world study evidencing a link between low LDL-P and reduced cardiovascular disease (CVD) risk. Data in the study published in Atherosclerosis demonstrated that high-risk patients who achieved a low LDL-P level experienced a 22-25 percent reduction in CVD risk compared to high-risk patients that achieved a low LDL-C level.
NMR-based Diabetes Risk Index (DRI) Helps to Identify Normal-weight Individuals at High Risk of Progressing to Type 2 Diabetes
PR Newswire - Sat Jun 14, 12:00PM CDT
LipoScience, Inc. (NASDAQ: LPDX), a diagnostic company pioneering a new field of personalized nuclear magnetic resonance (NMR) diagnostics to advance the quality of patient care in cardiovascular, metabolic and other diseases, today announced the presentation of data demonstrating the utility of the company's NMR-based diabetes risk index (DRI) in identifying normal-weight individuals at high risk of progressing to type 2 diabetes. The data, presented today in a poster session at the 74th Scientific Sessions of the American Diabetes Association (ADA), suggest that the DRI may enable more timely and focused risk assessment and intervention in at-risk individuals regardless of body weight, potentially preventing or slowing their progression to type 2 diabetes.
Patients Managed to Target LDL Particle Number Experience Fewer Cardiovascular Events Than Patients Managed to Target LDL Cholesterol, According to Study
PR Newswire - Mon Mar 31, 8:30AM CDT
LipoScience, Inc. (NASDAQ: LPDX), a diagnostic company pioneering a new field of personalized nuclear magnetic resonance (NMR) diagnostics to advance the quality of patient care in cardiovascular, metabolic and other diseases, today announced data showing that patients managed to a target LDL particle (LDL-P) number, as measured by LipoScience's NMR LipoProfile test, achieved a 22 to 25 percent greater reduction in the risk of cardiovascular (CV) events over a three-year period compared to patients who attained LDL cholesterol (LDL-C) targets.
Nasdaq stocks posting largest volume increases
AP - Fri Mar 28, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Why LipoScience (LPDX) Stock Hit a One-Year Low Today
at The Street - Fri Mar 28, 1:03PM CDT
LipoScience (LPDX) fell to a one-year low on Friday after the diagnostics technology company decreased its first-quarter guidance to less than analysts' estimates after it ended its contract with Health Diagnostic Laboratory. The company reduced its...